United States: FDA 2017 Year In Review: Refining Medical Device Pathways And Introducing Pilot Programs To Promote Quality

This is the third installment of our year-in-review series covering major developments at FDA. While the previous two installments, which can be found here and here, pertain to FDA actions on drugs and biologics, this post will address developments related to "traditional" medical devices and diagnostics (i.e., not software devices).

The Center for Devices and Radiological Health (CDRH) has had a busy year in 2017, and its activities appear to be in line with the general FDA strategy described in our prior installments: greater access to novel treatments through more consistent and efficient premarket review processes. We have seen guidance this year establishing premarket threshold criteria to ensure that a particular review process is appropriate, as well as guidance that may help speed up premarket review. CDRH also made significant progress developing new pilot programs as part of the Case for Quality initiative by establishing ground-breaking pilot programs and regulatory pathways for new technologies such as next generation sequencing (NGS) tests.

Making Device Review More Efficient

Helping Manufacturers Know When Review is Necessary

CDRH issued important guidance providing criteria for submitting a 510(k) for changes to an existing device and for FDA acceptance of a de novo application. In the final guidance, Deciding When to Submit a 510(k) for a Change to an Existing Device, CDRH describes a framework for determining whether a device modification is significant enough to require clearance under a new 510(k). The final guidance includes flow charts for common types of modifications (e.g., improvements to safety/effectiveness; labeling; technology, engineering, or performance; or materials) that provide a step-by-step guide through the decision making process. The draft guidance, Acceptance Review for De Novo Classification Requests, sets out FDA's criteria for determining whether the assigned review team should accept a de novo request for review or issue a "refuse to accept" notice. The guidance provides a checklist of preliminary questions, expected organizational elements, and recommended substantive content to illustrate in detail how the review team will arrive at its decision.

Both guidance documents will potentially increase the efficiency of 510(k) and de novo application reviews because they better enable manufacturers to self-select for submission and review. CDRH hopes that by providing clearer threshold criteria for device review, the number of incomplete or unnecessary applications will decrease, giving review teams more time to devote to complete submissions.

New Standards of Review

The Center also released two final guidance documents that create additional methods by which manufacturers can support regulatory decision making for a device. In Qualification of Medical Device Development Tools, CDRH describes the Medical Device Development Tool (MDDT) program by which interested entities may develop and qualify with FDA standardized methods, materials, or measurements that can assess the safety, effectiveness, or performance of medical devices. Through the MDDT program, CDRH encourages creation, qualification, and distribution of MDDTs to establish more efficient means by which manufacturers may test (and FDA may consider) device performance in the context of premarket review. Although we anticipate that adoption of this process in the industry will be relatively slow, introducing a method for standardized performance review could substantially increase turnaround for device substantial equivalence and approval decisions for certain devices.

The final guidance, Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices, lays out a general framework for CDRH's consideration of real-world evidence (RWE) as part of certain regulatory processes. The guidance describes FDA's current thinking that RWE should demonstrate certain recommended indicia of relevance and reliability in order to be accepted for consideration. While the guidance suggests that RWE may be suitable to support clearance or approval decisions, it is likely that, for the time being, RWE will only be considered as supplemental evidence and not as primary evidence of safety and effectiveness. Even so, the use of RWE can provide important data about real world use that could clarify certain issues for reviewers and reduce the number of interactive questions during review.

Streamlined Pathway for Next Generation Sequencing

Next generation sequencing (NGS) is a rapidly developing technology that allows technicians to quickly sequence the whole genome or all coding genes (whole exome) of an organism. NGS technology has many medical applications, but developing tests to map somatic and germline mutations related to cancer is one of the primary focuses of many laboratories. By mapping the whole genome or exome of cancer cells, a laboratory can identify biomarkers that are FDA-approved as companion diagnostics or that may offer clinical insights into possible effective treatments.

The regulatory status of NGS-based tumor profiling tests is uncertain because both in vitro diagnostic (IVD) manufacturers and developers of laboratory developed tests (LDTs) currently provide access to such tests. FDA has cleared or approved five NGS tests, four of which include companion diagnostic indications, but there are hundreds of competing LDTs available from CLIA-certified laboratories. Although FDA has not provided any insight into its current thinking about the specific regulation of NGS testing, the Centers for Medicare and Medicaid Services recently released a proposed national coverage determination that provides coverage and reimbursement for approved and cleared NGS-based tumor profiling tests while excluding similar LDTs from coverage.

In addition, on November 15, 2017, FDA announced the accreditation of the New York State Department of Health (NYSDOH) as a third-party reviewer for in vitro diagnostics. It also determined that any NGS-based tumor profiling test already reviewed and approved by NYSDOH would not require a 510(k) application for clearance. This decision suggests that FDA believes alternative methods other than FDA premarket review are available to confirm analytical and clinical validity of NGS tests. However, any developer seeking a companion diagnostic indication (Class III) for an NGS-based tumor profiling test must still go through the PMA process.

Quality-Centered Pilot Programs

Some of the most significant developments at CDRH relate to the Case for Quality initiative. The Case for Quality was launched in October 2011, and since then, CDRH has been developing the means to reliably measure manufacturer and device quality with the aim of developing a system that would encourage manufacturers to focus on increasing process and product quality instead of focusing on basic compliance with FDA regulations. Now that CDRH has developed metrics and assessment tools with the help of industry stakeholders, CDRH is rolling out four pilot programs that will test the effectiveness of this concept.

First, CDRH has already accepted an initial set of manufacturers to participate in the digital health software precertification pilot program, which will be discussed in more detail in the next post.

Second, the Center has announced a framework for the Voluntary Medical Device Manufacturing and Product Quality pilot program, which will allow enrolled device manufacturers to measure their quality systems against CDRH's maturity model and assess their ability to produce high quality devices and improve patient safety. Depending on the level of quality demonstrated, a participating manufacturer could experience faster review times and would be removed from FDA's routine inspection schedule in favor of a less intrusive evaluation method.

Third, CDRH initiated the Premarket Approval Application Critical to Quality pilot program on September 29, 2017. The goal of the pilot program is to enable applicants to discuss design and process quality information with the review team early in the PMA process to facilitate the review of submitted manufacturing information and the post-approval inspection. CDRH hopes to streamline PMA review by confirming that the applicant has implemented robust controls for aspects of the manufacturing process that are critical to device safety and effectiveness.

Fourth, CDRH and the Office of Regulatory Affairs have announced a joint pilot, the Voluntary Compliance Improvement Program, which allows participating manufacturer to self-identify and correct potential regulatory violations rather than undergo FDA inspection. Firms eligible for participation in the pilot will be selected and notified by FDA.

These pilot programs are consistent with FDA's strategy to alleviate the inspection system's significant strain on the limited resources of the Office of Compliance. While these quality-centered pilots may eventually prove to be superior methods of ensuring that manufacturers maintain robust quality systems, CDRH's methods for verifying quality and the consequences of violation still need to be established.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions